课题基金 / 基金详情

GH21-003, Advancing Public Health Research in Kenya

GH21-003, Advancing Public Health Research in Kenya
GH21-003,推进肯尼亚的公共卫生研究
批准号:
10472398
负责人:
M KARIUKI NJENGA
金额:
$742.7万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-30 至 2026-09-29

项目摘要

项目成果

M KARIUKI NJENGA的其他基金

相似基金

相关文献

中文摘要
翻译
摘要(行政核心) 我们的联盟由华盛顿州立大学(WSU)、利物浦热带医学院(LSTM)和 肯尼亚医学研究所(KEMRI)建议支持KEMRI开发和管理一个高成本效益的 和可持续KEMRI/CGHR研究平台(KRP)在肯尼亚西部(在“类别1。研究协调和 行政核心的“行政”)。该平台包括基于人口的健康和人口统计 监测系统,基苏穆和内罗毕的实验室,基苏穆的临床研究中心,以及办公室和共享 服务在基西安校园,基苏穆。在2014年至2020年期间,KRP的日常管理发生了三次变化 使其更加高效、透明、可负担,并减少与KEMRI、CDC和其他合作伙伴的争议。目前, 该平台由KEMRI管理,CDC(通过其合作伙伴)与其他合作伙伴一起提供资金 共享平台的国际合作伙伴。WSU和LSTM与KEMRI及其合作伙伴有着良好的关系 以及在肯尼亚多年的行政和技术专业知识。经过广泛的讨论和协议, 在此联合申请之前,WSU,LSTM和KEMRI中央领导将支持KEMRI/CGHR实施一项 管理计划,以加强该中心的能力,承担成本效益和可持续的管理, 支持他们在肯尼亚的公共卫生研究平台。这将包括分阶段实行财政和 行政管理系统,所有国家和国际机构共同商定的费用分摊制度 合作伙伴共享设施,WSU密切的财政监督,以及指导和培训。KEMRI已经对 精简平台管理层和加强其领导的步骤,包括任命三名高级官员, 工作人员在KEMRI/CGHR,修订政策,以加强决策在中心一级,并承诺提供 它的财政支持份额。它还包括推出一个电子系统,用于管理赠款, 道德应用。作为“类别2.研究实验室管理局”,我们将维持认可标准, 质量保证流程,以及集成的生物安全和生物安保系统,以支持KEMRI最先进的技术 laboratories.我们亦会引入实验室信息管理系统,包括有效管理 样本和相关数据。KEMRI实验室最近证明了它们对该国的效用, 国家对COVID-19大流行的检测能力。此外,我们还提供明显的技术专长, RFA确定的核心领域,包括艾滋病毒和结核病、疟疾、流感和其他呼吸道病原体, 人畜共患疾病、抗菌素耐药性、被忽视的热带疾病、非传染性疾病和疫苗- 可预防的疾病。经验丰富的WSU和LSTM科学家将与KEMRI和CDC同行合作设计, 实施和发表研究成果,这是一种旨在培训和指导KEMRI科学家应用和管理 科研经费在随附的研究核心提案中,这些团队描述了现场和实验室活动, 解决RFA的每一个必要成果和目标。本行政核心文件表5提供了一项工作计划, 如何在该计划的5年期间实施每项研究。
英文摘要
SUMMARY (ADMINISTRATIVE CORE) Our Consortium consisting of Washington State University (WSU), the Liverpool School of Tropical Medicine (LSTM), and the Kenya Medical Research Institute (KEMRI) proposes to support KEMRI to develop and manage a highly cost-effective and sustainable KEMRI/CGHR Research Platform (KRP) in western Kenya (under “Category 1. Research Coordination and Administration” of the administrative core). The platform includes the population-based health and demographic surveillance systems, laboratories in Kisumu and Nairobi, clinical research centers in Kisumu, and offices and shared services at the Kisian campus, Kisumu. Between 2014 and 2020, KRP’s day-to-day management was changed three times to make it more efficient, transparent, affordable, and less contentious with KEMRI, CDC, and other partners. Currently, the platform is managed by KEMRI, with CDC (through its partners) contributing financially together with the other international partners who share the platform. WSU and LSTM have an excellent relationship with KEMRI and its partners and many years of administrative and technical expertise in Kenya. Following extensive discussions and agreements leading up to this joint application, WSU, LSTM, and KEMRI central leadership will support KEMRI/CGHR to implement a management plan to strengthen the Center’s capacity to assume cost-effective and sustainable management of the platform in support of their public health research in Kenya. This will include a phased introduction of financial and administrative management systems, mutually agreed systems for cost-sharing across all national and international partners sharing the facilities, close fiscal oversight by WSU, and mentorship and training. KEMRI has already taken critical steps to streamline the platform’s management and strengthen its leadership, including the appointment of three senior staff at KEMRI/CGHR, the revision of policies to enhance decision-making at the Center level, and commitment to providing its share of financial support. It also includes the rolling out of an electronic system for the management of grant and ethics applications. As part of “Category 2. Research Laboratory Administration”, we will maintain accreditation standards, quality assurance processes, and integrated biosafety and biosecurity systems to support KEMRI state-of-the-art laboratories. We will also introduce a laboratory information management system, including for effective management of samples and associated data. The KEMRI laboratories recently demonstrated their utility to the country by providing >70% of the country’s testing capacity for COVID-19 pandemic. In addition, we present evident technical expertise to lead the Research Core areas identified in the RFA, including HIV and TB, malaria, influenza, and other respiratory pathogens, zoonotic diseases, antimicrobial resistance, neglected tropical diseases, non-communicable diseases, and vaccine- preventable diseases. Experienced WSU and LSTM scientists will team up with KEMRI and CDC counterparts to design, implement, and publish research, an approach designed to train and mentor KEMRI scientists in applying and managing research funding. In the accompanying Research Core proposals, these teams describe field and laboratory activities that address each required outcome and objective of the RFA. Table 5 of this Administrative Core provides a work plan showing how each study will be implemented over the program’s 5-year duration.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GH21-003, Advancing Public Health Research in Kenya
  • 批准号:
    10893917
  • 项目类别:
  • 资助金额:
    $55.57万
  • 财政年份:
    2021
  • 负责人:
    M KARIUKI NJENGA
  • 依托单位:
Emerging Infectious Diseases Research Center - East and Central Africa
  • 批准号:
    10464357
  • 项目类别:
  • 资助金额:
    $66.45万
  • 财政年份:
    2021
  • 负责人:
    M KARIUKI NJENGA
  • 依托单位:
GH21-003, Advancing Public Health Research in Kenya
  • 批准号:
    10630848
  • 项目类别:
  • 资助金额:
    $12.0万
  • 财政年份:
    2021
  • 负责人:
    M KARIUKI NJENGA
  • 依托单位:
GH21-003, Advancing Public Health Research in Kenya
  • 批准号:
    10693978
  • 项目类别:
  • 资助金额:
    $750.0万
  • 财政年份:
    2021
  • 负责人:
    M KARIUKI NJENGA
  • 依托单位:
国内基金
海外基金
SRSF3抑制剂SFI003逆转急性髓系白血病耐药性的功能与机制研究
  • 批准号:
    2026JJ60275
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    邢程
  • 依托单位:
新型溶瘤性HPV治疗性疫苗MATV003的构建和药效学研究
  • 批准号:
    JCZRMS202601746
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
基于JAK-STAT信号通路研究E003调控URSA的Th17/Treg免疫平衡的分子机制
  • 批准号:
    82360318
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    31.00万元
  • 批准年份:
    2023
  • 负责人:
    章志琴
  • 依托单位:
噬菌体PaoP5编码蛋白Orf003通过FleQ抑制铜绿假单胞菌运动的分子机制研究